請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64111
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊銘欽 | |
dc.contributor.author | Chi-Hao Chiu | en |
dc.contributor.author | 邱琦皓 | zh_TW |
dc.date.accessioned | 2021-06-16T17:30:29Z | - |
dc.date.available | 2013-09-17 | |
dc.date.copyright | 2012-09-17 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-16 | |
dc.identifier.citation | Ronald Andersen. (1968). A behavioral model of families' use of health services: Center for Health Administration Studies, University of Chicago.
Ronald Andersen. (1995). Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? Journal of Health and Social Behavior, 36(1), 1-10. Ronald Andersen, & Lu Ann Aday. (1978). Access to Medical Care in the U.S.: Realized and Potential. Medical Care, 16(7), 533-546. Mary E. Charlson, Peter Pompei, Kathy L. Ales, & C. Ronald MacKenzie. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373-383. doi: 10.1016/0021-9681(87)90171-8 RC Chen, SF Chang, CL Su, THH Chen, MF Yen, HM Wu, ZY Chen, & HH Liou. (2001). Prevalence, incidence, and mortality of PD. Neurology, 57(9), 1679-1686. Vincent de Groot, Heleen Beckerman, Gustaaf J. Lankhorst, & Lex M. Bouter. (2003). How to measure comorbidity: a critical review of available methods. Journal of Clinical Epidemiology, 56(3), 221-229. doi: 10.1016/s0895-4356(02)00585-1 Richard A. Deyo, Daniel C. Cherkin, & Marcia A. Ciol. (1992). Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology, 45(6), 613-619. doi: 10.1016/0895-4356(92)90133-8 Stewart A. Factor, & William J. Weiner. (2007). Parkinson's disease: diagnosis and clinical management. NY:Demos. Alvan Feinstein. (1970). The pre-therapeutic classification of co-morbidity in chronic disease. Journal of Chronic Diseases, 23(7), 455-468. doi: 10.1016/0021-9681(70)90054-8 Benoit I. Giasson, Ross Jakes, Michel Goedert, John E. Duda, Susan Leight, John Q. Trojanowski, & Virginia M. Y. Lee. (2000). A panel of epitope-specific antibodies detects protein domains distributed throughout human α-synuclein in lewy bodies of Parkinson's disease. Journal of Neuroscience Research, 59(4), 528-533. doi: 10.1002/(sici)1097-4547(20000215)59:4<528::aid-jnr8>3.0.co;2-0 Robert A. Hauser. (2011). Future Treatments for Parkinson's Disease: Surfing the PD Pipeline. International Journal of Neuroscience, 121(S2), 53-62. doi: doi:10.3109/00207454.2011.620195 Robert A. Hauser, Kelly E. Lyons, & Rajesh Pahwa. (2012). The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson's Disease. International Journal of Neuroscience, 122(7), 333-337. doi: doi:10.3109/00207454.2012.657381 Margaret M. Hoehn, & Melvin D. Yahr. (1967). Parkinsonism. Neurology, 17(5), 427. Andrew J Hughes, Susan E Daniel, Linda Kilford, & Andrew J Lees. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry, 55(3), 181-184. doi: 10.1136/jnnp.55.3.181 Daniel M. Huse, Kathy Schulman, Lucinda Orsini, Jane Castelli-Haley, Sean Kennedy, & Gregory Lenhart. (2005). Burden of illness in Parkinson's disease. [Comparative StudyResearch Support, Non-U.S. Gov't]. Mov Disord, 20(11), 1449-1454. doi: 10.1002/mds.20609 J. Lokk, S. Borg, J. Svensson, U. Persson, & G. Ljunggren. (2012). Drug and treatment costs in Parkinson’s disease patients in Sweden. Acta Neurologica Scandinavica, 125(2), 142-147. doi: 10.1111/j.1600-0404.2011.01517.x Cynthia L. Leibson, Kirsten Hall Long, Demetrius M. Maraganore, James H. Bower, Jeanine E. Ransom, Peter C. O'Brien, & Walter A. Rocca. (2006). Direct medical costs associated with Parkinson's disease: A population-based study. Movement Disorders, 21(11), 1864-1871. doi: 10.1002/mds.21075 W. Martin, O. Suchowersky, K.K. Burns, & E. Jonsson. (2010). Parkinson Disease: A Health Policy Perspective: John Wiley & Sons. (UK) National Collaborating Centre for Chronic Conditions (Ed.). (2006). Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians (UK). Olivier Rascol, Andres Lozano, Matthew Stern, & Werner Poewe. (2011). Milestones in Parkinson's disease therapeutics. Movement Disorders, 26(6), 1072-1082. doi: 10.1002/mds.23714 L. C. Tan, N. Venketasubramanian, C. Y. Hong, S. Sahadevan, J. J. Chin, E. S. Krishnamoorthy, A. K.Y. Tan, & S. M. Saw. (2004). Prevalence of Parkinson disease in Singapore. Neurology, 62(11), 1999-2004. doi: 10.1212/01.wnl.0000128090.79756.10 C. Vossius, M. Gjerstad, H. Baas, & J. P. Larsen. (2006). Drug costs for patients with Parkinson's disease in two different European countries. [Article]. Acta Neurologica Scandinavica, 113(4), 228-232. doi: 10.1111/j.1600-0404.2005.00574.x Gang Wang, Qi Cheng, Rui Zheng, Yu-Yan Tan, Xiao-Kang Sun, Hai-Yan Zhou, Xiao-Lai Ye, Ying Wang, Zeng Wang, Bo-Min Sun, & Sheng-Di Chen. (2006). Economic burden of Parkinson's disease in a developing country: A retrospective cost analysis in Shanghai, China. Movement Disorders, 21(9), 1439-1443. doi: 10.1002/mds.20999 Wang SJ, Fuh JL, Liu CY, Lin KP, Chang R, Yih JS, Chou P, Lin KN, Teng EL, Larson EB, et al. (1994). Parkinson's Disease in Kin-Hu, Kinmen: A Community Survey by Neurologists. Neuroepidemiology, 13(1-2), 69-74. Yaroslav Winter, Monika Balzer-Geldsetzer, Sonja von Campenhausen, Annika Spottke, Karla Eggert, Wolfgang H. Oertel, & Richard Dodel. (2010). Trends in resource utilization for Parkinson's disease in Germany. Journal of the Neurological Sciences, 294(1-2), 18-22. doi: 10.1016/j.jns.2010.04.011 Zhen-Xin Zhang, Gustavo C. Roman, Zhen Hong, Cheng-Bing Wu, Qiu-Ming Qu, Jue-Bing Huang, Bing Zhou, Zhi-Ping Geng, Ji-Xing Wu, Hong-Bo Wen, Heng Zhao, & Gwendolyn E. P. Zahner. (2005). Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. The Lancet, 365(9459), 595-597. doi: 10.1016/s0140-6736(05)17909-4 內政部. (2011). 內政部人口統計. 王冠懿, & 鄭守夏. (2006). 民眾就醫層級與醫療利用分析:SARS疫情前後的觀察. [The Analysis of Level of Outpatient Visits and Healthcare Utilization: A before and after Observation of the SARS Outbreak]. 臺灣公共衛生雜誌, 25(1), 75-82. 行政院健保局. (2010). 全民健康保險藥品給付規定. 台北: 行政院健保局. 吳怡瑤. (2006). 台灣地區帕金森氏病之藥物流行病學研究. 碩士, 高雄醫學大學, 高雄市. Retrieved from http://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi?o=dnclcdr&s=id=%22094KMC05551004%22.&searchmode=basic 徐偉成, 李超群, & 林欣榮. (2002). 巴金森氏症之全面觀. [Parkinson's Disease]. 志為護理-慈濟護理雜誌, 1(3), 8-16. 曾菁英. (2007). 台灣地區帕金森氏症之流行病學研究. 碩士, 高雄醫學大學, 高雄市. Retrieved from http://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi?o=dnclcdr&s=id=%22095KMC05534018%22.&searchmode=basic 黃文柱. (2003). 巴金森氏病的藥物治療. [Medical Treatment of Parkinson's Disease]. Acta Neurologica Taiwanica, 12(1), 43-57. 蔡維河, 侯素秋, 黎家銘, & 楊清泉. (2011). 台灣阿茲海默症病人確診前的門診醫療利用. [The Utilization of Ambulatory Care Services before the Diagnosis of Alzheimer's Disease in Taiwan]. 臺灣公共衛生雜誌, 30(4), 316-325. 衛生署. (2011). 衛生署全民健保醫療統計. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64111 | - |
dc.description.abstract | 研究背景與目的:巴金森氏症是一個慢性且漸進之神經退化疾病,好發於老年人族群,其盛行率僅次於阿茲海默氏症,是重要的老人疾病。病程初期之症狀不定也未必明顯,且至今未有生理指標可幫助確診,患者通常因出現症狀而就醫,卻無法得到解釋,造成四處求醫的現象。本研究主要目的在於探討巴金森氏症患者於確診前及後之門診醫療利用有無差異,透過此探討確診前後對病患就醫行為之影響。另外,亦探討巴金森氏症患者確診前、後之門診醫療利用,與非巴金森氏症之患者在同一段期間有無差異。
研究方法:本研究資料來自國家衛生研究院之全民健康保險研究資料庫之2005年一百萬人承保抽樣歸人檔,所使用之子檔包含門診處方及治療明細檔(CD)、醫事機構基本資料檔(HOSB)、住院醫療費用清單明細檔(DD)、門診處方醫令明細檔(OO)及承保資料檔(ID)。採用隨機對照研究,研究對象有兩組,分別為巴金森氏症確診個案(個案組)與非巴金森氏症者(對照組)。個案組擷取於2008年兩次主診斷碼為332.0,且前一年沒有此主診斷就醫紀錄之病人謂之確診,即納入個案(共222人),另外,經性別、年齡、查爾森共病指數等匹配後,使用1:2之比例隨機選取對照組(共444人),比較個案組確診前後一年期間,兩組樣本在同期間醫療利用的差異。使用配對樣本t檢定、獨立樣本t檢定及廣義估計方程式等統計方法進行分析。 研究結果:巴金森氏症患者確診後一年與確診前一年相比,門診利用次數無顯著改變,門診總費用增加,總藥費增加;巴金森氏症患者與非巴金森氏症之患者間,確診前一年及確診後一年總門診利用次數較多,門診費用較高;控制其他變項後,巴金森氏症患者相對於對照組確診後一年較確診前一年之總門診利用次數不變、神經科門診次數增加,門診總費用增加,門診總藥費增加、住院總次數無顯著改變、住院醫療費用無顯著改變。 研究結論:巴金森氏症患者與非巴金森氏症患者比較,不論確診前後,其利用門診之次數及費用均較多。且確診使巴金森氏症患者對於醫療利用之需求增加,個案組和對照組間之醫療利用差距更大。 | zh_TW |
dc.description.abstract | Background and objectives: Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder, which mostly appears in elderlies. As an important disease for old people, PD’s prevalence rate is slightly lower than that of Alzheimer’s disease. In the early stage of PD, the symptoms are not obvious. Until now, there is no physiology criteria used in PD diagnosis. Therefore, patient will seek for medical explanations by visiting multiple hospitals or clinics as PD’s symptom emerges. The aim of this study was to examine the medical utilization of the PD patients before and after they were diagnosed , and compare it with those who did not have PD to find out the impacts that PD on patients’ medical seeking behavior.
Methods: The data are selected from National Health Insurance Research Database from 2007 to 2009. As a case-control design is used, we have 2 groups of study targets. A total 222 patients diagnosed with PD (ICD-9 code 332.0), treated with PD medications in 2008 and without any PD diagnosis in 2007 are the case group. Other 444 patients who were randomly match by sex, age and “level of the most frequently visited institution” serves as control group. The medical care utilization by the case group within 1 year before and after diagnosis is explored and compared to that of the control group. The study used paired-sample t test, independent two sample t test and General Estimation Equation (GEE) to test the hypotheses. Results: The ambulatory expenditure (total fees, drug fees) of PD patients after diagnosis was significantly higher than they did before diagnosis, while the number of ambulatory visits did not have significant change. PD patients used significantly more ambulatory services (total clinics visits, total fee) than control group before and after diagnosis. The diagnosis has no significant effect on hospitalization care. Conclusions: PD patients used significantly more ambulatory services than control group before and after diagnosis. The diagnosis increases the medical need of PD patients. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T17:30:29Z (GMT). No. of bitstreams: 1 ntu-101-R99848016-1.pdf: 516894 bytes, checksum: e405d3b7d9405983e0eba42da6dd2f97 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 致謝 I
中文摘要 II Abstract IV 目錄 VI 圖目錄 VIII 表目錄 IX 第一章 緒論 1 第一節 研究背景與動機 1 第二節 研究目的 2 第三節 研究重要性 2 第二章 文獻探討 3 第一節 巴金森氏症之簡介 3 一、 盛行率 3 二、 巴金森氏症之疾病分類 3 三、 巴金森氏症之臨床表徵 4 四、 巴金森氏症之疾病診斷 6 五、 巴金森氏症之治療 7 第二節 醫療服務利用的理論 9 第三節 查爾森共病指數 11 第四節 巴金森氏症醫療利用實證研究 14 第五節 綜合討論 16 第三章 研究材料與方法 17 第一節 研究架構 17 第二節 研究假說 18 第三節 研究材料 19 第四節 研究變項及操作型定義 21 第五節 資料處理及分析方法 23 第四章 研究結果 25 第一節 描述性統計 25 一、 個案組與對照組研究樣本的特質(表4-1、表4-2) 25 二、 個案組與對照組研究樣本之醫療資源利用情形(表4-3、表4-4) 26 第二節 推論性統計 33 一、 巴金森氏症個案組確診前後一年醫療資源利用之分析 33 二、 個案組及對照組於確診前後一年醫療資源利用之分析 35 三、 巴金森氏症個案組及對照組確診前後一年醫療資源利用多變項分析 38 第五章 討論 56 第一節 重要研究結果討論 56 第二節 研究限制 60 第六章 結論與建議 61 第一節 結論 61 第二節 建議 62 參考文獻 63 | |
dc.language.iso | zh-TW | |
dc.title | 台灣巴金森氏症患者確診前後一年醫療利用及其與非巴金森氏症患者之比較 | zh_TW |
dc.title | The utilization of health care services before and after the diagnosis of Parkinson’s disease and the comparison with those without Parkinson’s disease in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李玉春,蔡淑鈴 | |
dc.subject.keyword | 巴金森氏症,醫療利用,廣義估計方程式, | zh_TW |
dc.subject.keyword | Parkinson’s disease,Medical utilization,General Estimate Equation (GEE), | en |
dc.relation.page | 65 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-16 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 504.78 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。